Ocaliva (Obeticholic Acid) Patent Expiration, LOE Window & CMS Spending

Ocaliva (Obeticholic Acid) by Intercept: FDA Orange Book core substance LOE 2033-06-17 (last listed 2036-04-26), 0 AB generics, $208.1M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIntercept
FDA Application & PathwayN207999 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-06-17
Last Listed Patent or Exclusivity Date2036-04-26
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$208.1M
2024 Medicare Part D Spend$185.0M
2024 Medicaid Spend$23.1M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 25.8% 2-yr change)